Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-22

Study Completion Date

2024-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835

Acute Kidney Injury Due to Sepsis

RECRUITING PHASE2

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

NCT05524051

Acute Kidney Injury Following Cardiac Surgery

TERMINATED PHASE2

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

NCT05624723

Renal Insufficiency Kidney Diseases

COMPLETED PHASE1

A Study in Sepsis Patients With Renal Failure

NCT00511186

Sepsis Bacterial Infections and Mycoses

TERMINATED PHASE2

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

NCT02182440

Acute Kidney Injury

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a multicenter, participant and investigator-blinded, randomized, placebo-controlled study to characterize PK/PD profile and to evaluate the safety and the tolerability of TIN816. The study enrolled hospitalized adult participants with a diagnosis of sepsis and acute kidney injury (AKI). 20 participants were randomized in the study. The study consisted of a screening period (24-48 hours), a treatment period (day 1), and post-treatment period (days 2 to 90).

Screening took place during hospitalization in a intensive care unit (ICU) (or intermediate/high dependency unit (HDU care) where potential participants were undergo screening to assess the presence of sepsis and AKI. Pre-identified participants provided informed consent and went to screening assessments to determine eligibility. Potential study candidates were hospitalized patients with a diagnosis of sepsis based on Sepsis 3 criteria with suspected or confirmed infection and SOFA score ≥ 2 after excluding the renal component, and a diagnosis of AKI stage 1 or greater. At Treatment Day 1, participants who meet eligibility criteria at screening and baseline were randomized in a 3:1 ratio to treatment with TIN816 or placebo by intravenous infusion in a participant and investigator-blinded fashion.

Treatment day 1 was followed by a 90 day post-treatment period for pharmocokinetic, pharmacodynamic, safety and tolerability assessments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Due to Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TIN816

Administered as an intravenous dose

Group Type EXPERIMENTAL

TIN816 70 mg lyophilisate powder

Intervention Type BIOLOGICAL

Recombinant human CD39 enzyme

Placebo

0.9% sterile sodium chloride solution administered as an intravenous dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

0.9% sterile sodium chloride solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TIN816 70 mg lyophilisate powder

Recombinant human CD39 enzyme

Intervention Type BIOLOGICAL

Placebo

0.9% sterile sodium chloride solution

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent must be obtained prior to participation in the study.
2. ≥ 18 and ≤ 85 years of age.
3. Admitted to ICU or intermediate/HDU.
4. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:

Suspected or confirmed infection SOFA score of 2 or more (excluding renal component)
5. Diagnosis of AKI Stage 1 or greater per the following criterion at randomization :

An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference creatinine baseline.

For hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI should be used as reference baseline, otherwise, baseline serum creatinine in the following order of preference:

Median value within 3 months of the hospital admission. If not available:

Median value between 3 and 6 months prior to hospital admission. If not available:

At hospital admission.

8. Presence of AKI for a period longer than 48 hours prior to study drug administration as suggested by clinical manifestations, e.g., prolonged oliguria or severe renal dysfunction (eg, serum creatinine \> 4 mg/dL) on admission without a history of CKD.
9. Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization.
10. AKI is most likely attributable to causes other than sepsis such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides), other medical conditions (e.g. heart failure, liver failure, acute abdominal aortic aneurysm, dissection, renal artery stenosis) or urinary obstruction.
11. Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN).
12. Patients who are post-nephrectomy.
13. Patients who are on dual antiplatelet therapy.
14. Patients who are thrombocytopenic at screening (Platelet count \<100,000 microliter) or other high risk for bleeding in the opinion of the investigator.
15. Immunosuppressed patients:

History of immunodeficiency diseases or known HIV test positive. Is receiving immunosuppressant treatment or is on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with hydrocortisone (e.g., 3 × 100 mg) can be included.
16. Active hepatitis (defined as (a) abnormal liver enzymes (Alanine aminotransferase (ALT), Gamma-glutamyl transferase (GGT), ALP \> 3x Upper Limit of Normal (ULN) or (b)) for active hepatitis B or C infection, a positive Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) serology or patients with advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C).
17. Acute pancreatitis with no established source of infection.
18. Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable).
19. Burns requiring ICU treatment.
20. Sepsis attributed to confirmed COVID-19.
21. Use of other investigational drugs within 5 half-lives of enrollment within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
22. History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes.
23. Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement.
24. Women with a positive pregnancy test, pregnancy or breast feeding.
25. Women of child-bearing potential

Exclusion Criteria

1. Not expected to survive for 24 hours.
2. Not expected to survive for 30 days due to medical conditions other than SA-AKI.
3. History of CKD with a documented estimated GFR \<45 ml/min prior to development of AKI.
4. Receiving RRT or a decision has been made to initiate RRT within 24 hours of admission.
5. Weight is less than 40 kg or more than 125 kg .
6. Has life support limitations (eg, do not resuscitate, do not dialyze, do not intubate).

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No